A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer

Investigational New Drugs

Volumn 21, Issue 1, 2003, Pages 103-107

  Goel, Sanjay ^a,b   Wadler, Scott ^c   Hoffman, Anthony ^a   Volterra, Fabio ^a   Baker, Cheryl ^a,b   Nazario, Elliot ^a,b   Ivy, Percy ^d   Silverman, Alyson ^a,b   Mani, Sridhar ^a,b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Colorectal cancer; Phase II; Rebeccamycin analog

Indexed keywords

1,11 DICHLORO 6 (2 DIETHYLAMINOETHYL) 12,13 DIHYDRO 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 (4 O METHYLGLUCOSIDE); REBECCAMYCIN;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MALE; METASTASIS; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TUMOR GROWTH; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 0038691825     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022980613420     Document Type: Article

References (16)

1. Lam KS, Schroeder DR, Veitch JM, Colson KL, Matson JA, Rose WC, Doyle TW, Forenza S: Production, isolation and structure determination of novel fluoroindolocarbazoles from Saccharothrix aerocolonigenes ATCC 39243. J Antibiot Tokyo 54: 1-9, 2001
2. Kaneko T, Wong H, Utzig J, Schurig J, Doyle T: Water soluble derivatives of rebeccamycin. J Antibiot Tokyo 43: 125-127, 1990
3. Pearce CJ, Doyle TW, Forenza S, Lam KS, Schroeder DR: The biosynthetic origins of rebeccamycin. J Nat Prod 51: 937-940, 1988
4. Bush JA, Long BH, Catino JJ, Bradner WT, Tomita K: Production and biological activity of rebeccamycin, a novel antitumor agent. J Antibiot Tokyo 40: 668-678, 1987
5. Gilbert EJ, Chisholm JD, Van Vranken DL: Conformational Control in the Rebeccamycin Class of Indolocarbazole Glycosides. J Org Chem 64: 5670-5676, 1999
6. Prudhomme M: Recent developments of rebeccamycin analogues as topoisomerase I inhibitors and antitumor agents. Curr Med Chem Rev 7: 1189-1212, 2002
7. Arimondo PB, Bailly C, Boutorine A, Sun JS, Garestier T, Helene C: Targeting topoisomerase I cleavage to specific sequences of DNA by triple helix-forming oligonucleotide conjugates. A comparison between a rebeccamycin derivative and camptothecin. CR Acad Sci III 322: 785-790, 1999
8. Tolcher AW, Eckhardt SG, Kuhn J, Hammond L, Weiss G, Rizzo J, Aylesworth C, Hidalgo M, Patnaik A, Schwartz G, Felton S, Campbell E, Rowinsky EK: Phase I and pharmaco-kinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. J Clin Oncol 19: 2937-2947, 2001
9. Dowlati A, Hoppel CL, Ingalls ST, Majka S, Li X, Sedransk N, Spiro T, Gerson SL, Ivy P, Remick SC: Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days. J Clin Oncol 19: 2309-2318, 2001
10. Weitman S, Moore R, Barrera H, Cheung NK, Izbicka E, Von Hoff DD: In vitro antitumor activity of rebeccamycin analog (NSC# 655649) against pediatric solid tumors. Pediatr Hematol Oncol 20: 136-139, 1998
11. Ibrahim D, Hussain M, LoRusso P, Flaherty L: Rebeccamycin analog (BMY-27557-14) in renal cell cancer (RCC): Preliminary results of a phase II trial. Abstract # 2373. Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology, 2001
12. Bailly C, Colson P, Houssier C, Rodrigues-Pereira E, Prudhomme M, Waring MJ: Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin. Mol Pharmacol 53: 77-87, 1998
13. Bailly C, Riou JF, Colson P, Houssier C, Rodrigues-Pereira E, Prudhomme M: DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin. Biochemistry 36: 3917-3929, 1997
14. Investigator's Brochure: Rebeccamycin Analog NSC 655649
15. Miller AB, Hoodgstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000